Morgan Stanley Reiterates Equal-Weight on Hologic

Morgan Stanley reiterated its Equal-weight rating on Hologic HOLX. At the moment, the rating agency does not have a price target placed on the company's stock. On Monday, HOLX lost 2.8% of its value to finish the day at $18.05. Its shares continued to slide in today's pre-market trading, falling 1.44% to stand around $17.79.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: ReiterationAnalyst RatingsHealth CareHealth Care EquipmentMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!